Shots: The P-III trial involves assessing the safety, immunogenicity and PK of EG12014 (trastuzumab, biosimilar) vs Herceptin in 807 patients in a ratio (1:1) for HER2-positive breast cancer The trial […]readmore
Tags : HER2-positive Breast Cancer
Shots: The approval is based on P-III FeDeriCa study evaluating the pharmacokinetics, efficacy, and safety of Phesgo + CT vs Perjeta + Herceptin (IV) + CT in 500 patients with […]readmore
Shots: The approval is based on P-III SOPHIA trial involves assessing of Margenza (IV, 15 mg/kg, q3w) vs Herceptin (trastuzumab, IV, 6mg/kg or 8mg/kg for loading dose) both combined with […]readmore
Shots: The approval is based on P-III FeDeriCa study which involves assessing of Phesgo (SC) + CT vs Perjeta (pertuzumab, IV) & Herceptin (trastuzumab, IV) + CT in 500 patients […]readmore
Shots: HER2CLIMB study involves assessing of Tukysa (tucatinib) + trastuzumab + capecitabine vs trastuzumab + capecitabine alone in 612 patients in a ratio (2:1) with LA unresectable/m-HER2+ BC prior treated […]readmore
Shots: The BLA is based on P-III FeDeriCa study assessing FDC of Perjeta + Herceptin (SC) + CT vs Perjeta + Herceptin (IV) + CT in 500 patients with HER2-positive […]readmore
Shots: The P-III FeDeriCa study involves assessing of Perjeta (pertuzumab) and Herceptin (trastuzumab) as FDC in SC formulation + CT (IV) vs its standard IV Infusion formulation + CT in […]readmore